Please provide your email address to receive an email when new articles are posted on . In a new study published in Chest, cardiovascular events occurred in 30% of patients with bronchiectasis after ...

Please provide your email address to receive an email when new articles are posted on . Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and ...

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...

Targeting airway inflammation with investigational brensocatib reduced exacerbations with bronchiectasis, the ASPEN trial showed. The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate ...

Prior exacerbations and greater symptom severity independently predicted future exacerbations in patients with bronchiectasis. Long-term macrolide proved beneficial not only for patients with frequent ...

August 22, 2012 — A new application of a drug that was approved in 1996 and has been widely used since significantly decreased the frequency of exacerbations and increased the time to first ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...